NCT02215070View on ClinicalTrials.gov

Pasireotide in Prevention of GI Toxicity

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 21, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

October 15, 2019

Conditions
Hematological Malignancies
Interventions
DRUG

Pasireotide

Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.

Trial Locations (2)

27705

Duke University Medical Center, Durham

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Anthony Sung, MD

OTHER

NCT02215070 - Pasireotide in Prevention of GI Toxicity | Biotech Hunter | Biotech Hunter